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Abstract: A series of fifteen new N-alkoxyphenylanilides of 3-hydroxynaphthalene-2-
carboxylic acid was prepared and characterized. Primary in vitro screening of the synthesized 
compounds was performed against Staphylococcus aureus, three methicillin-resistant  
S. aureus strains, Mycobacterium tuberculosis H37Ra and M. avium subsp. paratuberculosis. 
OPEN ACCESS
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Some of the tested compounds showed antibacterial and antimycobacterial activity against 
the tested strains comparable with or higher than that of the standards ampicillin or rifampicin. 
3-Hydroxy-N-(2-propoxyphenyl)naphthalene-2-carboxamide and N-[2-(but-2-yloxy)-phenyl]-
3-hydroxynaphthalene-2-carboxamide had MIC = 12 µM against all methicillin-resistant  
S. aureus strains; thus their activity is 4-fold higher than that of ampicillin. The second 
mentioned compound as well as 3-hydroxy-N-[3-(prop-2-yloxy)phenyl]-naphthalene-2-
carboxamide had MICs = 23 µM and 24 µM against M. tuberculosis respectively. N-[2-
(But-2-yloxy)phenyl]-3-hydroxynaphthalene-2-carboxamide demonstrated higher activity 
against M. avium subsp. paratuberculosis than rifampicin. Screening of the cytotoxicity of 
the most effective antimycobacterial compounds was performed using THP-1 cells, and no 
significant lethal effect was observed for the most potent compounds. The compounds 
were additionally tested for their activity related to inhibition of photosynthetic electron 
transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. N-(3-Ethoxyphenyl)-3-
hydroxynaphthalene-2-carboxamide (IC50 = 4.5 µM) was the most active PET inhibitor. 
The structure-activity relationships are discussed. 
Keywords: hydroxynaphthalene-2-carboxanilides; in vitro antibacterial activity; in vitro 
antimycobacterial activity; in vitro cytotoxicity; photosynthetic electron transport inhibition; 
structure-activity relationships 
 
1. Introduction 
Recent studies have shown that, despite antibacterial therapy, methicillin-resistant  
Staphylococcus aureus (MRSA) infections are still associated with serious clinical consequences, 
especially treatment failure, higher morbidity and mortality [1], prolonged hospitalization [2], increased 
health care costs [2], etc. Activity against MRSA is of a great importance in the new generation of 
antibacterial agents because of the worldwide increasing prevalence of this pathogen [3], more frequent 
antibiotic resistance to available anti-MRSA drugs, their toxicity and general lack of oral agents [4]. 
Tuberculosis (TB), caused by Mycobacterium tuberculosis and its multidrug-resistant (MDR) or 
extensively drug-resistant (XDR) strains also remains one of the world’s deadliest communicable 
diseases. In 2013, an estimated 9.0 million people developed TB and 1.5 million died from the disease. 
Drug resistance surveillance data indicate that in 2013 approximately 480,000 people developed 
MDR-TB worldwide. XDR-TB has been identified in 100 countries globally as of 2013, and the 
average proportion of MDR-TB cases with XDR-TB was 9.0% [5]. Because of M. tuberculosis, the 
pathogenic role of non-tuberculous mycobacteria (NTM) in humans was overshadowed for a long 
time. NTM have become more prevalent human pathogens, causing difficult-to-treat or incurable 
diseases, potentially ending in death when the patient is immunocompromised. NTM can cause a  
broad spectrum of diseases, such as pulmonary disease, lymphadenitis, skin and soft tissue disease, 
gastrointestinal and skeletal infections. They are resistant to standard antimycobacterial therapy, but 
may be susceptible to some standard antibiotics. However, the resistance to these antibiotics develops 
quickly [6]. 
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3-Hydroxynaphthalene-2-carboxamides can be considered as cyclic analogues of salicylanilides that 
have expressed promising results as potential antimicrobial and antimycobacterial agents ([7,8] and refs. 
therein). The anti-infectious effect is connected with the ability of salicylanilides to inhibit various 
enzymatic systems in bacteria, e.g., two-component regulatory systems (TCS), transglycosylases from 
Staphylococcus aureus (but not from M. tuberculosis), D-alanine-D-alanine ligase, isocitrate lyase and 
methionine aminopeptidase ([7,8] and refs. therein). They serve also as inhibitors of protein kinase 
epidermal growth factor receptor and are generally designed to compete with ATP for binding in 
catalytic domain of tyrosin kinase [9] or as selective inhibitors of interleukin-12p40 production [10]. 
Since 3-hydroxy-N-(methoxyphenyl)naphthalene-2-carboxamide showed activity against 
Staphylococcus strains and against mycobacterial species [11], other alkoxy derivatives were designed 
as homologues of those methoxyphenyl derivatives. The present work is focused on synthesis and 
investigation of the biological activity of N-alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides as 
promising antibacterial and antimycobacterial agents. Additionally all the compounds were tested for 
their ability to inhibit the photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) 
chloroplasts using the Hill reaction. This idea is based on the fact that both pharmaceuticals and 
pesticides are designed to target particular biological functions, and in some cases these functions 
overlap in their molecular target sites, or they target similar processes or molecules. Taking into the 
consideration that herbicides may also have molecular sites of action in mammals, until recently most 
pharmaceutical companies had pesticide divisions, and all compounds generated by either division of 
the company were evaluated for both pesticide and pharmaceutical uses. In the past, some leading 
pesticides have become pharmaceuticals and vice versa [12–15]. Moreover, a good correlation between 
microbiological activity and herbicidal effect was described in previous studies [16–23]. 
2. Results and Discussion 
2.1. Chemistry 
The condensation of 3-hydroxynaphthalene-2-carboxylic acid with the appropriate alkoxy-substituted 
anilines using phosphorus trichloride in dry chlorobenzene under microwave conditions yielded a 
series of nineteen N-substituted 3-hydroxynaphthalene-2-carboxanilides 2–8c. Unique commercially 
unavailable alkoxyanilines 1a–o were prepared by a modified procedure according to De Marco et al. [24] 
using direct alkylation of corresponding aminophenols by alkylbromides in the presence of sodium 
hydride, see Scheme 1. Compounds 3a–8c have not been described in literature so far. Compounds 2–3c 
were published by Kos et al. [11], nevertheless they are also mentioned here to provide a complete 
overview of biological activities and structure-activity relationships. 
The well-known physicochemical descriptors such as lipophilicity, surface tension of compounds, 
electronic parameters and molar volume of substituents are largely employed in structure-activity 
relationship analysis. In a number of studies examining biological activity of potential drugs, the 
relationship between lipophilicity or other descriptors and their potency have been investigated. In the 
current investigation the calculated lipophilicity (log P) and the surface tension of the compounds as 
well as the molar volume of R substituents (see Table 1), were used to determine if these factors play  
a role in their biological activity. 
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Reagents and conditions: (a) R-Br, NaH, acetonitrile, RT, 24 h; (b) 3-hydroxynaphthalene-2-carboxylic acid, 
PCl3, chlorobenzene, MW, 15 min. 
Scheme 1. Synthesis of N-alkoxyphenyl-3-hydroxynaphthalene-2-carboxanilides. 
Table 1. Structures of the discussed ring-substituted 3-hydroxynaphthalene-2-carboxanilides 
2–8c; calculated values of log P, surface tension (ST [dyne/cm]) and molar volume (MV 
[cm3]) of R substituents; in vitro antibacterial activity (MIC) of compounds in comparison 
with ampicillin (APC) standard; in vitro antimycobacterial activity (MIC) of compounds in 
comparison with rifampicin (RIF) standard; in vitro cytotoxicity assay (LD50) of chosen 
compounds; and IC50 values related to PET inhibition in spinach chloroplasts in comparison 
with 3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) standard. 
Comp. R1 log P a 
MV a 
[cm3] 
ST a 
[dyne/cm] 
[µM] 
MIC 
LD50 
PET 
IC50 SA 
MRSA 
63718 
MRSA 
SA 630 
MRSA 
3202 
MT MAP 
2 H 4.52 0 0 972 972 972 972 950 950 >30 ND 
3a 2-OCH3 4.61 37.15 58.71 55 55 55 55 51 205 >30 59.5 
3b 3-OCH3 4.56 37.15 58.71 873 873 873 873 51 426 >30 53.4 
3c 4-OCH3 4.37 37.15 58.71 873 873 873 873 852 852 >30 ND 
4a 2-OC2H5 4.92 53.66 56.66 832 832 832 832 813 813 >30 76.1 
4b 3-OC2H5 4.88 53.66 56.66 832 832 832 832 813 813 >30 4.5 
4c 4-OC2H5 4.67 53.66 56.66 832 832 832 832 813 813 >30 ND 
5a 2-OC3H7 5.26 70.16 54.92 12.4 12.4 12.4 12.4 778 778 >30 128 
5b 3-OC3H7 5.21 70.16 54.92 796 796 796 796 778 778 >30 4.8 
5c 4-OC3H7 5.27 70.16 54.92 796 796 796 796 778 778 >30 ND 
6a 2-OC4H9 5.60 86.67 53.42 763 763 763 763 373 745 >30 182 
6b 3-OC4H9 5.54 86.67 53.42 763 763 763 763 745 745 16.5 ± 0.8 7.8 
6c 4-OC4H9 5.60 86.67 53.42 763 763 763 763 745 745 >30 ND 
7a 2-OCH(CH3)2 5.18 70.54 53.79 796 796 796 796 389 778 >30 138 
7b 3-OCH(CH3)2 5.13 70.54 53.79 796 796 796 796 24 778 27.4 ± 0.6 6.9 
7c 4-OCH(CH3)2 5.11 70.54 53.79 796 796 796 796 389 778 >30 ND 
8a 2-OCH(CH3)C2H5 5.52 87.05 52.38 5.9 11.9 11.9 11.9 23 89 >30 134 
8b 3-OCH(CH3)C2H5 5.47 87.05 52.38 763 763 763 763 23 745 2.7 ± 0.7 8.3 
8c 4-OCH(CH3)C2H5 5.46 87.05 52.38 763 763 763 763 89 745 >30 ND 
APC – − – – 5.7 >46 >46 >46 – – – – 
RIF – − – – – – – – 10 109 – – 
DCMU – − − − – – – – – – – 1.9 
a calculated using ACD/Percepta ver. 2012; SA = S. aureus ATCC 29213, MRSA = clinical isolates of 
methicillin-resistant S. aureus 63718, SA 630 and 3202; MT = M. tuberculosis H37Ra, MAP = clinical 
isolate of M. avium subsp. paratuberculosis CIT03; ND = not determined due to precipitation. 
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2.2. In Vitro Antibacterial Susceptibility Testing 
The in vitro antibacterial activity of the discussed compounds was evaluated against three clinical 
isolates of MRSA and S. aureus ATCC 29213 as a reference and quality control strain. All the 
compounds showed only moderate or negligible activity, except methoxy derivative 3a [11], propoxy 
derivative 5a and sec-butoxy one 8a. The activity of compound 3a is comparable with that of the 
standard; the activity of derivatives 5a and 8a is almost 4-fold higher than that of ampicillin. Based on 
the results presented in Table 1 it seems that the antibacterial efficacy is closely connected with  
ortho-substitution of the aniline ring and with the even-numbered length alkoxy chain. It is positively 
influenced by higher lipophilicity as well as increasing surface activity (i.e., decreasing surface 
tension) of the compounds. The lipophilicity of the discussed compounds is influenced by the length 
and branching of the alkoxy tail of the R substituent, and it seems that anti-Staphylococcus potency is 
affected also by increasing bulkiness/molar volume of the alkoxy chain. 
2.3. In Vitro Antimycobacterial Evaluation 
The evaluation of the in vitro antimycobacterial activity of the compounds was performed against 
M. tuberculosis H37Ra ATCC 25177 [25] and clinical isolate of M. avium subsp. paratuberculosis 
CIT03 [26], see Table 1. The activity of compounds was expressed as the minimum inhibitory 
concentration (MIC) that is defined for mycobacteria as a 90% or greater (IC90) reduction of growth in 
comparison with the control. The MIC/IC90 value is routinely and widely used in bacterial assays, 
being a standard detection limit according to the Clinical and Laboratory Standards Institute [27]. 
Most of compounds did not show any antimycobacterial activity, except ortho- and meta-position 
isomers 8a,b (R = 2-, 3-OCH(CH3)C2H5) and compound 7b (R = 3-OCH(CH3)2) that demonstrated the 
highest activity against M. tuberculosis (MIC = 23 µM for 8a,b and 24 µM for 7b) within the discussed 
series of compounds. Compound 8a (R = 2-OCH(CH3)C2H5) also exhibited higher activity against  
M. avium subsp. paratuberculosis than rifampicin. Due to limited number of the effective compounds 
it is not possible to formulate a more comprehensive SAR hypothesis. Based on the results presented 
in Table 1 it seems that the activity is positively influenced by increasing surface activity of the 
compounds and substitution in the ortho- and meta-position, especially by branched chains. An increasing 
antimycobacterial activity caused by branched chains was described recently [28,29]. 
Additionally, a standard MTT assay was performed on the selected most effective compounds, the 
MICs of which were previously determined through Alamar Blue assays (see Table 1). The MTT assay 
is a well-characterized method of assessing cell growth through measurement of respiration. For the 
purpose of this assay, an MTT measured viability of M. tuberculosis H37Ra of less than 70% after 
exposure to the MIC of each tested compound was considered a positive result. As such, a low level of 
cell viability may suggest inhibition of cell growth through respiratory inhibition [30]. All the selected 
compounds, i.e., 3-isopropoxy (7b, 10.7%), 2-sec-butoxy (8a, 23.9%) and 3-sec-butoxy (8b, 21.7%) 
derivatives showed less than 70% viability of M. tuberculosis H37Ra at the lowest tested concentration 
(8 µg/mL, i.e., ca. 24 µM). 
Janin [31] discusses a similar type of carboxamides in his review and suggested the hypothesis  
that all these compounds can interfere with the mycobacterial proton pump F0F1H+ATPase or inhibit 
biosynthesis of amino acids. Based on the fact that the change in the colour of Alamar Blue is caused 
Molecules 2015, 20 9772 
 
 
by a decrease of mycobacterial cell metabolism, it may be hypothesized that the mechanism of action 
of these N-alkoxyphenylamides of 3-hydroxynaphthalene-2-carboxylic acid could be connected with  
an effect on mycobacterial energy metabolism [32], however, we cannot rule out the possibility that 
the studied compounds acted upon a salicylanilides-like site present in the mycobacteria, as mentioned 
above ([7,8] and refs. therein). 
2.4. In Vitro Cytotoxicity Assay 
The preliminary in vitro screening of the cytotoxicity of the compounds was performed using  
the human monocytic leukemia THP-1 cell line. The cytotoxicity was evaluated as the LD50 value 
(LD50—lethal dose to 50% of the cell population), see Table 1. A compound is considered cytotoxic 
when it demonstrates a toxic effect on cells at concentrations up to 10 μM [33], and the highest tested 
concentration that was used for the toxicity assay was three times this value. Treatment with  
30 μM by a majority of compounds did not lead to significant lethal effects on THP-1 cells. Compound 
7b (R = 3-OCH(CH3)2) demonstrated low toxicity (LD50 = 27.5 ± 0.5 µM) against THP-1. Compound 
6b (R = 3-OC4H9) showed an LD50 of 16.5 ± 0.8 µM, while 8b (R = 3-OCH(CH3)C2H5) exerted fairly 
high toxicity (LD50 = 2.7 ± 0.7 µM; e.g., the LD50 of oxaliplatin against this cell line was formerly 
measured as 1.7 ± 0.6 µM). It can be stated that cytotoxicity is closely connected with the substitution 
of the meta-position of aniline and increases with a longer and branched tail, i.e., it seems that 
cytotoxicity increases with increasing bulkiness of the alkoxy chain as well as increasing surface 
activity of the compounds (i.e., surface tension decrease), see 5b (LD50 >30 μM, MV = 70.16 cm3,  
ST = 54.92 dyne/cm) < 7b (LD50 = 27.5 µM, MV = 70.54 cm3, ST = 53.79 dyne/cm) << 6b  
(LD50 = 16.5 µM, MV = 86.67 cm3, ST = 53.42 dyne/cm) <<< 8b (LD50 = 2.7 µM, MV = 87.05 cm3,  
ST = 52.38 dyne/cm). Based on these observations it can be concluded that anilides with LD50 > 30 μM 
3a, 5a, 4b, 5b and especially the most potent 8a can be considered as promising agents for subsequent 
design of novel antibacterial and antimycobacterial agents, respectively. 
2.5. Inhibition of Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
As it was found that antimicrobial activity correlates with herbicidal effect, all the studied compounds 
were additionally evaluated also for their activity related to photosynthetic electron transport (PET) 
inhibition in spinach chloroplasts, which was reflected in the inhibition of photoreduction of artificial 
electron acceptor 2,6-dichlorophenol-indophenol. The PET inhibiting activity of the compounds was 
expressed by IC50 values. The most active compounds were meta-substituted derivatives. The aqueous 
solubility of the para-substituted compounds was limited; therefore IC50 values could not be determined 
due to precipitation of compounds during experiment. Compounds 4b (R = 3-OC2H5; IC50 = 4.5 μM), 
5b (R = 3-OC3H7; IC50 = 4.8 μM) and 7b (R = 3-OCH(CH3)2; IC50 = 6.9 μM) are effective PET 
inhibitors (IC50 of the standard DCMU was 1.9 μM). 
The dependences of PET-inhibiting activity expressed as log(1/IC50) on the lipophilicity (log P)  
of the compounds, surface tension (ST [dyne/cm]) as well as on the molar volume (MV [cm3]) of 
individual alkoxy chains are illustrated in Figure 1A–C. The dependence of the PET-inhibiting activity 
of the ortho-substituted derivatives on the lipophilicity of the compounds and the molar volume of 
individual alkoxy tails linearly decreased (r = −0.9454, n = 6 and r = −0.9439, n = 6), see Figure 1A,B. 
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The PET inhibition linearly increased with increasing surface tension, i.e., decreasing surface activity, 
see Figure 1C. 
On the other hand, the dependences of the PET-inhibiting activity of meta-substituted compounds 
on physicochemical parameters were biphasic. The PET inhibition rapidly increased from log P = 4.56 
(R = 3-OCH3, 3b) to log P = 4.88 (R = 3-OC2H5, 4b) and with the further increase of compound 
lipophilicity and the bulkiness of the alkoxy chain it slowly decreased indicating that the prolongation 
and branching of the alkoxy chain is connected with an activity drop. Also the PET inhibition linearly 
increased with increasing surface tension (i.e., with surface activity decreasing) to ST = 56.66 dyne/cm 
(compound 4b) and then rapidly decreased up to ST = 58.71 dyne/cm (compound 3b), see Figure 1C. 
It is important to note that, while the increase in the antimicrobial activity and the cytotoxicity is 
connected especially with the extension of the alkoxy tail and the increase in surface activity, effective 
PET inhibitors are typically characterized by lower surface activity and rather short and unbranched 
alkoxy chains. However, it should be mentioned that although both methoxy derivatives 3a and 3b 
showed similar PET inhibition and were characterized by similar calculated parameters, compound 3a 
was the most effective within the ortho-substituted series, while compound 3b was the least potent 
within the meta-substituted series. 
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Figure 1. Dependence of PET inhibition log(1/IC50)[M] of tested compounds on lipophilicity 
expressed as log P (A); molar volume (MV [cm3]) of individual alkoxy chains (B); and 
surface tension (ST [dyne/cm]) (C). 
By the addition of 1,5-diphenylcarbazide (DPC), an artificial electron donor acting in Z●/D● 
intermediate on the donor side of PS II [34], to chloroplasts treated with the studied compounds,  
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in which PET was inhibited by about 85%–94%, PET was practically completely restored only in  
the presence of very high DPC concentrations (approx. 2.3 mM). As DPC can alter the binding of 
compounds with herbicidal activity, e.g., atrazin or metribuzin, presumably due to overlapping binding 
domain in the QB pocket but its effect on the QB site can affect plastoquinone reduction only at 
relatively high concentrations (>2 M) [35,36], it could be assumed that the inhibitory site of action of 
the studied compounds is situated on the acceptor side of PS II, in the section at QB site. Previously it 
was found that PET on the acceptor side of PS II was partially damaged also by ring-substituted 
salicylanilides and carbamoylphenylcarbamates [37], ring-substituted 4-arylamino-7-chloroquinolinium 
chlorides [38], 5-tert-butyl-6-chloro-N-(3-fluorophenyl)pyrazine-2-carboxamide and 5-tert-butyl-N-(3-
hydroxy-4-chlorophenyl)pyrazine-2-carboxamide [39] and by N-benzylpyrazine-2-carboxamides [40]. 
The studied compounds affected chlorophyll a (Chla) fluorescence in spinach chloroplasts indicating 
their interactions with constituents of photosynthetic apparatus. Fluorescence emission spectra of  
Chla in spinach chloroplasts treated with compound 4b are shown in Figure 2. The decreased intensity 
of the emission band at 686 nm belonging to the Chla-protein complexes occurring mainly in 
photosystem II [41] suggested PS II as the site of action of the studied inhibitors. The extent of 
perturbation of Chla-protein complexes in the thylakoid membrane is reflected in the sharpness of 
decreased fluorescence of Chla pigment. A similar decrease of Chla fluorescence in plant chloroplasts 
was also observed previously after treatment with ring-substituted 1-hydroxynaphthalene-2-
carboxanilides [17], 2-hydroxynaphthalene-1-carboxanilides [18], 5-bromo- and 3,5-dibromo-2-hydroxy-
N-phenyl-benzamides [42] and ring-substituted 4-arylamino-7-chloroquinolinium chlorides [38]. 
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Figure 2. Fluorescence emission spectra of chlorophyll a in untreated spinach chloroplasts 
in presence of compound 4b: 0, 102, 204, 408 and 612 μM (curves from top to bottom);  
λex = 436 nm. 
3. Experimental Section 
3.1. General Information 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Merck (Darmstadt, 
Germany). Reactions were carried out in StartSYNTH microwave labstation (Milestone, Sorisole, 
Italy). TLC experiments were performed on alumina-backed silica gel 40 F254 plates (Merck). The 
Molecules 2015, 20 9775 
 
 
plates were illuminated under UV (254 nm) and evaluated in iodine vapour. The melting points were 
determined on Kofler hot-plate apparatus HMK (Franz Kustner Nacht KG, Dresden, Germany) and are 
uncorrected. Infrared (IR) spectra were recorded on a Smart MIRacle™ ATR ZnSe for Nicolet™ 
Impact 410 FT-IR spectrometer (Thermo Electron Corporation, West Palm Beach, FL, USA). All  
1H- and 13C-NMR spectra were recorded on an Avance III 400 MHz FT-NMR spectrometer (Bruker, 
Karlsruhe, Germany) in DMSO-d6. 1H and 13C chemical shifts (δ) are reported in ppm using signal of 
the solvent as a standard (2.500 and 39.50 ppm). Mass spectra were measured using a LTQ Orbitrap 
Hybrid Mass Spectrometer (Thermo Electron Corporation) with direct injection into an APCI source 
(400 °C) in the positive mode. Lipophilicity (log P) of the final compounds, surface tension and  
molar volume of R substituents were predicted using ACD/Percepta ver. 2012 (Advanced Chemistry 
Development, Inc., Toronto, ON, Canada). 
3.2. Synthesis 
3.2.1. General Procedure for the Synthesis of Anilines 1a–1o 
These syntheses were carried out in one step as per De Marco et al. [24] Aminophenol (92 mmol) 
and a suspension of NaH in mineral oil (275 mmol NaH) were suspended in dry DMF (100 mL). The 
corresponding alkylbromide (137 mmol) was added dropwise and the mixture was then stirred for 24 h 
at room temperature. The reaction was quenched by adding 400 mL of distilled water and the aqueous 
layer was extracted with 3 × 150 mL of ethyl acetate. Collected organic layers were dried over anhydrous 
Na2SO4 and concentrated in vacuo. Pure product was obtained by distillation under reduced pressure. 
2-Ethoxyaniline (1a). Yield 70%; bp. 109–111 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.76 (d,  
J = 8.0 Hz, 1H); 6.61–6.66 (m, 2H); 6.47–6.54 (m, 1H); 4.62 (s, 2H); 3.97 (q, J = 7.0 Hz, 2H); 1.33 (t, 
J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6), δ: 145.53, 137.78, 120.88, 116.25, 113.96, 111.79, 63.28, 14.86. 
3-Ethoxyaniline (1b). Yield 80%; bp. 125–127 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.88 (t,  
J = 8.4 Hz, 1H); 6.11–6.16 (m, 2H); 6.02–6.08 (m, 1H); 5.00 (s, 2H); 3.89 (q, J = 7.0 Hz, 2H); 1.28 (t, 
J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6), δ: 159.55, 149.96, 129.54, 106.78, 102.08, 99.97, 62.38, 14.81. 
4-Ethoxyaniline (1c). Yield 78%; bp: 126–128 °C (10 mmHg) [43]; 1H-NMR (DMSO-d6), δ: 6.63 (d,  
J = 8.8 Hz, 2H); 6.49 (d, J = 8.8 Hz, 2H); 4.57 (s, 2H); 3.85 (q, J = 7.0 Hz, 2H); 1.25 (t, J = 7.0 Hz, 
3H); 13C-NMR (DMSO-d6), δ: 149.86, 142.29, 115.29, 114.99, 63.31, 14.90. 
2-Propoxyaniline (1d). Yield 63%; bp. 127–129 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.75 (d,  
J = 8.0 Hz, 1H); 6.62–6.67 (m, 2H); 6.49–6.54 (m, 1H); 4.62 (s, 2H); 3.87 (t, J = 6.6 Hz, 2H); 1.73 (sx, 
J = 7.0 Hz, 2H); 0.99 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 145.165, 137.75, 120.82, 116.28, 
113.96, 111.60, 69.16, 22.25, 10.56. 
3-Propoxyaniline (1e). Yield 73%; bp. 125–127 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.87 (t,  
J = 8.4 Hz, 1H); 6.11–6.15 (m, 2H); 6.03–6.08 (m, 1H); 5.00 (s, 2H); 3.79 (t, J = 6.6 Hz, 2H); 1.67 (sx, 
J = 7.0 Hz, 2H); 0.95 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 159.69, 149.95, 129.51, 106.73, 
102.08, 100.01, 68.39, 22.16, 10.46. 
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4-Propoxyaniline (1f). Yield 73%; bp. 129–131 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.63 (d,  
J = 8.8 Hz, 2H); 6.49 (d, J = 8.8 Hz, 2H); 4.57 (s, 2H); 3.76 (t, J = 6.6 Hz, 2H); 1.65 (sx, J = 7.0 Hz, 
2H); 0.94 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 149.98, 142.19, 115.32, 114.90, 69.45,  
22.16, 10.35. 
2-Butoxyaniline (1g). Yield 68%; bp. 133–135 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.75 (d,  
J = 8.0 Hz, 1H); 6.62–6.68 (m, 2H); 6.48–6.53 (m, 1H); 4.62 (s, 2H); 3.90 (t, J = 6.4 Hz, 2H); 1.70 (qi, 
J = 7.2 Hz, 2H); 1.43 (sx, J = 7.3 Hz, 2H); 0.94 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 145.71, 
137.71, 120.80, 116.25, 113.96, 111.60, 67.35, 31.19, 19.10, 13.73. 
3-Butoxyaniline (1h). Yield 70%; bp. 136–139 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.87 (t,  
J = 8.4 Hz, 1H); 6.11–6.14 (m, 2H); 6.03–6.08 (m, 1H); 5.00 (s, 2H); 3.83 (t, J = 6.4 Hz, 2H); 1.65 (qi, 
J = 7.2 Hz, 2H); 1.40 (sx, J = 7.3 Hz, 2H); 0.91 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 159.71, 
149.93, 129.49, 106.73, 102.08, 100.01, 66.55, 30.90, 18.80, 13.72. 
4-Butoxyaniline (1i). Yield 79%; bp. 132–135 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.63 (d,  
J = 8.8 Hz, 2H); 6.49 (d, J = 8.8 Hz, 2H); 4.57 (s, 2H); 3.79 (t, J = 6.4 Hz, 2H); 1.62 (qi, J = 7.2 Hz, 
2H); 1.39 (sx, J = 7.3 Hz, 2H); 0.91 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 150.04, 142.27, 
115.34, 114.97, 67.59, 31.03, 18.80, 13.75. 
2-(Prop-2-yloxy)aniline (1j). Yield 52%; bp. 107–110 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.78 
(d, J = 8.0 Hz, 1H); 6.63–6.66 (m, 2H); 6.48–6.54 (m, 1H); 4.60 (s, 2H); 4.45 (septet, J = 6.0 Hz, 1H); 
1.25 (d, J = 6.0 Hz, 6H); 13C-NMR (DMSO-d6), δ: 144.23, 138.76, 120.90, 116.26, 114.29, 113.80, 
70.23, 22.03. 
3-(Prop-2-yloxy)aniline (1k). Yield 56%; bp. 118–120 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.86 
(t, J = 8.4 Hz, 1H); 6.10–6.13 (m, 2H); 6.02–6.07 (m, 1H); 4.98 (s, 2H); 4.43 (septet, J = 6.0 Hz, 1H); 
1.21 (d, J = 6.0 Hz, 6H); 13C-NMR (DMSO-d6), δ: 158.45, 149.99, 129.56, 106.70, 103.29, 101.30, 
68.53, 22.04. 
4-(Prop-2-yloxy)aniline (1l). Yield 62%; bp. 130–132 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.62 
(d, J = 8.8 Hz, 2H); 6.48 (d, J = 8.8 Hz, 2H); 4.59 (s, 2H); 4.30 (septet, J = 6.0 Hz, 1H); 1.17 (d,  
J = 6.0 Hz, 6H); 13C-NMR (DMSO-d6), δ: 148.51, 142.54, 117.46, 114.99, 70.08, 22.07. 
2-(But-2-yloxy)aniline (1m). Yield 56%; bp. 112–113 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.76 
(d, J = 8.0 Hz, 1H); 6.62–6.66 (m, 2H); 6.46–6.52 (m, 1H); 4.56 (s, 2H); 4.24 (sx, J = 6.0 Hz, 1H);  
1.48–1.70 (m, 2H); 1.20 (d, J = 6.2 Hz, 3H); 0.92 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 144.44, 
138.77, 120.92, 116.26, 114.29, 113.82, 74.85, 28.68, 19.23, 9.59. 
3-(But-2-yloxy)aniline (1n). Yield 60%; bp. 120–123 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.86 (t, 
J = 8.4 Hz, 1H); 6.09–6.13 (m, 2H); 6.02–6.08 (m, 1H); 4.98 (s, 2H); 4.20 (sx, J = 6.0 Hz, 1H);  
1.45–1.65 (m, 2H); 1.18 (d, J = 6.2 Hz, 3H); 0.89 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 158.79, 
149.99, 129.56, 106.70, 103.32, 101.35, 73.61, 28.73, 19.27, 9.65. 
Molecules 2015, 20 9777 
 
 
4-(But-2-yloxy)aniline (1o). Yield 64%; bp. 132–133 °C (10 mmHg); 1H-NMR (DMSO-d6), δ: 6.62 (d, 
J = 8.8 Hz, 2H); 6.48 (d, J = 8.8 Hz, 2H); 4.59 (s, 2H); 4.06 (sx, J = 6.0 Hz, 1H); 1.45–1.65 (m, 2H); 
1.13 (d, J = 6.2 Hz, 3H); 0.89 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 148.83, 142.51, 117.49, 
114.97, 75.26, 28.67, 19.24, 9.62. 
3.2.2. General Procedure for the Synthesis of Carboxamide Derivatives 2–8c 
3-Hydroxynaphthalene-2-carboxylic acid (5.3 mmol) and the appropriate alkoxyaniline (5.3 mmol) 
were suspended in dry chlorobenzene (25 mL). Phosphorous trichloride (0.23 mL, 2.7 mmol) was 
added dropwise, and the reacting mixture was heated in the microwave reactor at maximal allowed 
power 500 W and 130 °C, using infrared flask-surface control of temperature, for 15 min. The solvent 
was evaporated under reduced pressure and the solid residue washed with 50 mL of 2 M HCl. The 
crude product was recrystallized from aqueous ethanol. 
3-Hydroxy-N-phenylnaphthalene-2-carboxamide (2), 3-hydroxy-N-(2-methoxyphenyl)naphthalene-2-
carboxamide (3a), 3-hydroxy-N-(3-methoxyphenyl)naphthalene-2-carboxamide (3b) and 3-hydroxy-N-
(4-methoxyphenyl)naphthalene-2-carboxamide (3c) were synthesized and characterized recently [11]. 
N-(2-Ethoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (4a). Yield 61%; Mp. 157–160 °C; IR 
(Zn/Se ATR, cm−1): 3418, 2974, 2888, 1662, 1603, 1589, 1538, 1455, 1441, 1393, 1343, 1312, 1293, 
1249, 1216, 1142, 1116, 1033, 924, 871, 789, 742; 1H-NMR (DMSO-d6), δ: 11.67 (s, 1H), 11.19 (s, 
1H), 8.72 (s, 1H), 8.56 (d, J = 7.0 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.52 (td, 
J = 7.0 Hz, 1.5 Hz, 1H), 7.30–7.40 (m, 2H), 7.06–7.09 (m, 2H), 6.93–7.04 (m, 1H), 4.15 (q, J = 7.0 Hz, 
2H), 1.47 (t, J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6), δ: 162.54, 152.54, 147.67, 135.77, 132.63, 
128.93, 128.32, 128.17, 127.19, 125.59, 123.77, 123.68, 121.36, 120.56, 119.72, 111.85, 110.69, 
64.14, 14.71; HR-MS: for C19H17NO3 [M+H]+ calculated 308.12812 m/z, found 308.12860 m/z. 
N-(3-Ethoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (4b).Yield 56%; Mp. 173–175 °C; IR 
(Zn/Se ATR, cm−1): 2973, 1623, 1593, 1549, 1532, 1458, 1399, 1362, 1266, 1215, 1178, 1158, 1133, 
1109, 1050, 921, 882; 1H-NMR (DMSO-d6), δ: 11.30 (s, 1H), 10.55 (s, 1H), 8.48 (s, 1H), 7.93 (d,  
J = 7.7 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.47–7.54 (m, 2H), 7.26–7.40 (m, 4H), 6.68–6.74 (m, 1H), 
4.03 (q, J = 7.0 Hz, 2H), 1.35 (t, J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6), δ: 165.59, 158.76, 153.65, 
139.55, 135.71, 130.40, 129.48, 128.63, 128.05, 126.81, 125.70, 123.68, 121.77, 112.57, 110.51, 
110.02, 106.73, 62.96, 14.57; HR-MS: for C19H17NO3 [M+H]+ calculated 308.12812 m/z, 
found 308.12869 m/z. 
N-(4-Ethoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (4c). Yield 49%; Mp. 221–224 °C; IR 
(Zn/Se ATR, cm−1): 3052, 2975, 2929, 1635, 1619, 1609, 1564, 1558, 1510, 1394, 1357, 1346, 1247, 
1214, 1172, 1146, 1119,1070, 1047, 949; 1H-NMR (DMSO-d6), δ: 11.47 (s, 1H), 10.51 (s, 1H), 8.53 
(s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.51 (td,  
J = 7.0 Hz, 1.5 Hz, 1H), 7.36–7.40 (m, 1H), 7.32 (s, 1H), 6.95 (d, J = 9.2 Hz, 2H), 4.02 (q, J = 7.0 Hz, 
2H), 1.33 (t, J = 7.0 Hz, 3H); 13C-NMR (DMSO-d6), δ: 165.59, 155.15, 154.15, 135.76, 131.15, 
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130.08, 128.61, 128.04, 126.75, 125.70, 123.64, 122.27, 120.93, 114.39, 110.56, 63.09, 14.59; HR-MS: 
for C19H17NO3 [M+H]+ calculated 308.12812 m/z, found 308.12857 m/z. 
3-Hydroxy-N-(2-propoxyphenyl)naphthalene-2-carboxamide (5a). Yield 89%; Mp. 164–166 °C; IR 
(Zn/Se ATR, cm−1): 3432, 2964, 2936, 2874, 1652, 1607, 1538, 1520, 1456, 1446, 1343, 1310, 1293, 
1215, 1172, 1149, 1115, 1041, 1018, 873; 1H-NMR (DMSO-d6), δ: 11.62 (s, 1H), 11.11 (s, 1H), 8.72 
(s, 1H), 8.55 (d, J = 7.4 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.53 (td, J = 7.0 Hz, 
1.2 Hz, 1H), 7. 41 (s, 2H), 7.32 (td, J = 7.0 Hz, 1.0 Hz, 2H), 6.93–7.09 (m, 1H), 4.05 (t, J = 6.6 Hz, 
2H), 1.86 (sx, J = 7.0 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H); 13C-NMR (DMSO-d6), δ: 162.60, 152.59, 
147.81, 135.78, 132.65, 128.93, 128.16, 128.16, 127.17, 125.59, 123.77, 123.77, 121.34, 120.43, 119.89, 
111.66, 110.71, 69.89, 22.11, 10.44; HR-MS: for C20H19NO3 [M+H]+ calculated 322.14377 m/z, found 
322.14435 m/z. 
3-Hydroxy-N-(3-propoxyphenyl)naphthalene-2-carboxamide (5b). Yield 71%; Mp. 170–173 °C; IR 
(Zn/Se ATR, cm−1): 2962, 2936, 2899, 2870, 1635, 1620, 1591, 1549, 1538, 1447, 1394, 1343, 1257, 
1223, 1211, 1157, 1048, 1027; 1H-NMR (DMSO-d6), δ: 11.29 (s, 1H), 10.55 (s, 1H), 8.48 (s, 1H), 7.94 
(d, J = 8.7 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.51 (td, J = 6.6 Hz, 1.5 Hz, 1H), 7.48 (s, 1H), 7.26–7.40 
(m, 4H), 6.70–6.74 (m, 1H), 3.93 (t, J = 6.6 Hz, 2H), 1.75 (sx, J = 7.0 Hz, 2H), 0.99 (t, J = 7.3 Hz, 
3H); 13C-NMR (DMSO-d6), δ: 165.60, 158.93, 153.66, 139.55, 135.71, 130.40, 129.48, 128.63, 
128.05, 126.81, 125.71, 123.68, 121.75, 112.57, 110.53, 110.07, 106.76, 68.91, 21.96, 10.31; HR-MS: 
for C20H19NO3 [M+H]+ calculated 322.14377 m/z, found 322.14420 m/z. 
3-Hydroxy-N-(4-propoxyphenyl)naphthalene-2-carboxamide (5c). Yield 66%; Mp. 219–221 °C; IR 
(Zn/Se ATR, cm−1): 2975, 2962, 2926, 1653, 1616, 1559, 1506, 1473, 1451, 1391, 1358, 1348, 1239, 
1210, 1170, 1068, 981, 951, 913; 1H-NMR (DMSO-d6), δ: 11.48 (s, 1H), 10.51 (s, 1H), 8.54 (s, 1H), 
7.92 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 9.2 Hz, 2H), 7.51 (td, J = 6.6 Hz,  
1.1 Hz, 1H), 7.36 (td, J = 5.1 Hz, 1.10 Hz, 1H), 7.33 (s, 1H), 6.95 (d, J = 9.2 Hz, 2H), 3.92 (t, J = 6.6 Hz, 
2H), 1.73 (sx, J = 6.6 Hz, 2H), 0.98 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 165.60, 155.32, 
154.16, 135.76, 131.15, 130.11, 128.61, 128.05, 126.75, 125.70, 123.64, 122.27, 120.90, 114.44, 
110.57, 69.07, 21.98, 10.29; HR-MS: for C20H19NO3 [M+H]+ calculated 322.14377 m/z, found 
322.14429 m/z. 
N-(2-Butoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (6a). Yield 63%; Mp. 156–159 °C; IR 
(Zn/Se ATR, cm−1): 3143, 2956, 2926, 2872, 1637, 1622, 1609, 1594, 1559, 1549, 1492, 1456, 1394, 
1358, 1343, 1287, 1251, 1222, 1208, 1116, 1065, 1035, 1006, 864; 1H-NMR (DMSO-d6), δ: 11.59 (s, 
1H), 11.09 (s, 1H), 8.72 (s, 1H), 8.54 (d, J = 7.4 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.79 (d, J = 8.1 Hz, 
1H), 7.53 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.41 (s, 1H), 7.36 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.09–6.97 (m, 
3H), 4.08 (t, J = 6.6 Hz, 2H), 1.83 (qi, J = 6.6 Hz, 2H), 1.50 (sx, J = 7.3 Hz, 2H), 0.97 (t, J = 7.3 Hz, 
3H); 13C-NMR (DMSO-d6), δ: 162.63, 152.62, 147.84, 135.82, 132.71, 128.99, 128.25, 128.17, 
127.20, 125.65, 123.84, 123.82, 121.36, 120.49, 119.92, 111.71, 110.77, 68.04, 30.97, 18.97, 13.65; 
HR-MS: for C21H21NO3 [M+H]+ calculated 336.15942 m/z, found 336.15980 m/z. 
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N-(3-Butoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (6b). Yield 56%; Mp. 153–155 °C; IR 
(Zn/Se ATR, cm−1): 2958, 2937, 2870, 1635, 1616, 1594, 1558, 1454, 1447, 1397, 1278, 1224, 1213, 
1174, 1158, 1064, 1042, 1014, 977, 875, 857; 1H-NMR (DMSO-d6), δ: 11.30 (s, 1H), 10.55 (s, 1H), 
8.48 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.51 (td, J = 6.1 Hz, 1.4 Hz, 1H), 7.47 
(s, 1H), 7.22–7.39 (m, 4H), 6.68–6.74 (m, 1H), 3.97 (t, J = 6.2 Hz, 2H), 1.72 (qi, J = 6.6 Hz, 2H), 1.45 
(sx, J = 7.7 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 165.60, 158.94, 153.66, 
139.54, 135.71, 130.37, 129.46, 128.63, 128.07, 126.81, 125.71, 123.68, 121.75, 112.57, 110.53, 
110.07, 106.76, 67.10, 30.67, 18.67, 13.60; HR-MS: for C21H21NO3 [M+H]+ calculated 336.15942 m/z, 
found 336.15972 m/z. 
N-(4-Butoxyphenyl)-3-hydroxynaphthalene-2-carboxamide (6c). Yield 63%; Mp. 211–214 °C; IR 
(Zn/Se ATR, cm−1): 3053, 2956, 2937, 2871, 1635, 1616, 1557, 1511, 1394, 1357, 1248, 1216, 1171, 
1070, 1039, 950; 1H-NMR (DMSO-d6), δ: 11.47 (s, 1H), 10.50 (s, 1H), 8.53 (s, 1H), 7.92 (d, J = 8.1 Hz, 
1H), 7.76 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 9.2 Hz, 2H), 7.51 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.36 (td,  
J = 7.0 Hz, 1.5 Hz, 1H), 7.32 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 3.96 (t, J = 6.6 Hz, 2H), 1.70 (qi,  
J = 8.1 Hz, 2H), 1.44 (sx, J = 8.1 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C-NMR (DMSO-d6), δ: 165.60, 
155.35, 154.16, 135.79, 131.19, 130.14, 128.67, 128.11, 126.79, 125.76, 123.71, 122.27, 121.04, 
114.46, 110.59, 67.28, 30.76, 18.71, 13.68; HR-MS: for C21H21NO3 [M+H]+ calculated 336.15942 m/z, 
found 336.15982 m/z. 
3-Hydroxy-N-[2-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (7a). Yield 71%; Mp. 196–198 °C; 
IR (Zn/Se ATR, cm−1): 3335, 2981, 2972, 2913, 1652, 1635, 1605, 1592, 1539, 1486, 1453, 1409, 
1373, 1340, 1284, 1221, 1176, 1118, 1069, 950, 924, 863, 835, 733, 690; 1H-NMR (DMSO-d6), δ: 
11.65 (s, 1H), 11.19 (s, 1H), 8.72 (s, 1H), 8.58 (dd, J = 7.7 Hz, 1.8 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 
7.79 (d, J = 8.4 Hz, 1H), 7.52 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.41 (s, 1H), 7.36 (td, J = 8.0 Hz, 1.8 Hz, 
1H), 6.96–7.14 (m, 3H), 4.69–4.75 (m, 1H), 1.36 (d, J = 5.9 Hz, 6H); 13C-NMR (DMSO-d6), δ: 
162.40, 152.51, 146.38, 135.77, 132.71, 129.45, 128.95, 128.16, 127.19, 125.59, 123.77, 123.57, 
121.42, 120.65, 119.83, 113.64, 110.68, 71.01, 21.84; HR-MS: for C20H19NO3 [M+H]+ calculated 
322.14377 m/z, found 322.14433 m/z. 
3-Hydroxy-N-[3-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (7b). Yield 98%; Mp. 162–164 °C; 
IR (Zn/Se ATR, cm−1): 3024, 2970, 2909, 1637, 1622, 1586, 1557, 1532, 1452, 1257, 1221, 1170, 
1152, 1116, 1001, 874, 776, 758, 740, 668; 1H-NMR (DMSO-d6), δ: 11.30 (s, 1H), 10.54 (s, 1H), 8.47 
(s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.51 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.45 (s, 
1H), 7.36 (td, J = 7.0 Hz, 1.5 Hz, 1H), 7.33 (s, 1H), 7.24–7.28 (m, 2H), 6.68–6.73 (m, 1H), 4.52–4.66 
(m, 1H), 1.29 (d, J = 5.9 Hz, 6H); 13C-NMR (DMSO-d6), δ: 165.65, 157.76, 152.66, 139.69, 135.76, 
130.45, 129.60, 128.72, 128.14, 126.88, 125.79, 123.77, 122.01, 112.51, 111.24, 110.54, 107.89, 
69.25, 21.85; HR-MS: for C20H19NO3 [M+H]+ calculated 322.14377 m/z, found 322.14433 m/z. 
3-Hydroxy-N-[4-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (7c). Yield 70%; Mp. 205–207 °C; 
IR (Zn/Se ATR, cm−1): 2978, 1653, 1602, 1558, 1505, 1452, 1346, 1237, 1210, 1172, 1120, 1108, 
1070, 951, 871, 839, 826, 742, 712; 1H-NMR (DMSO-d6), δ: 11.47 (s, 1H), 10.50 (s, 1H), 8.52 (s, 1H), 
7.92 (d, J = 7.7 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.51 (t, J = 7.0 Hz, 1H), 
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7.36 (td, J = 7.3 Hz, 1.1 Hz, 1H), 7.32 (s, 1H), 6.94 (d, J = 8.8 Hz, 2H), 4.56–4.62 (m, 1H), 1.27 (d,  
J = 5.9 Hz, 6H); 13C-NMR (DMSO-d6), δ: 165.57, 154.13, 154.04, 135.74, 131.10, 130.10, 128.61, 
128.04, 126.73, 125.70, 123.64, 122.28, 120.96, 115.78, 110.54, 69.38, 21.78; HR-MS: for C20H19NO3 
[M+H]+ calculated 322.14377 m/z, found 322.14435 m/z. 
N-[2-(But-2-yloxy)phenyl]-3-hydroxynaphthalene-2-carboxamide (8a). Yield 74%; Mp. 147–149 °C; 
IR (Zn/Se ATR, cm−1): 2971, 1653, 1634, 1616, 1592, 1538, 1488, 1454, 1398, 1340, 1287, 1252, 
1221, 1127, 1117, 1067, 983, 921, 864, 836, 739; 1H-NMR (DMSO-d6), δ: 11.61 (s, 1H), 11.17 (s, 
1H), 8.72 (s, 1H), 8.57 (dd, J = 7.7 Hz, 1.1 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 
7.52 (td, J = 7.0 Hz, 1.1 Hz, 1H), 7.41 (s, 1H), 7.36 (td, J = 7.0 Hz, 1.1 Hz, 1H), 6.91–7.12 (m, 3H), 
4.51 (sx, J = 5.9 Hz, 1H), 1.57–1.90 (m, 2H), 1.31 (d, J = 5.9 Hz, 3H), 0.97 (t, J = 7.3 Hz, 3H);  
13C-NMR (DMSO-d6), δ: 162.43, 152.52, 146.65, 135.76, 132.71, 129.25, 128.93, 128.16, 127.19, 
125.59, 123.77, 123.60, 121.42, 120.46, 119.90, 113.27, 110.66, 75.78, 28.50, 19.12, 9.56; HR-MS: 
for C21H21NO3 [M+H]+ calculated 336.15942 m/z, found 336.15980 m/z. 
N-[3-(But-2-yloxy)phenyl]-3-hydroxynaphthalene-2-carboxamide (8b). Yield 71%; Mp. 152–155 °C; 
IR (Zn/Se ATR, cm−1): 2967, 2918, 2873, 1637, 1623, 1590, 1544, 1451, 1267, 1224, 1155, 1133, 
1092, 1066, 1005, 915, 881, 869, 847, 765, 748, 709; 1H-NMR (DMSO-d6), δ: 11.29 (s, 1H), 10.54 (s, 
1H), 8.48 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.51 (td, J = 7.0 Hz, 1.1 Hz, 1H), 
7.47 (s, 1H), 7.36 (td, J = 8.1 Hz, 1.1 Hz, 1H), 7.33 (s, 1H), 7.25–7.28 (m, 2H), 6.67–6.73 (m, 1H), 
4.36 (sx, J = 6.2 Hz, 1H), 1.50–1.80 (m, 2H), 1.25 (d, J = 5.9 Hz, 3H), 0.94 (t, J = 7.3 Hz, 3H);  
13C-NMR (DMSO-d6), δ: 165.63, 158.09, 153.66, 139.67, 135.74, 130.42, 129.57, 128.69, 128.11, 
126.87, 125.77, 123.74, 121.97, 112.45, 111.25, 110.53, 107.89, 74.23, 28.56, 19.05, 9.55; HR-MS: 
for C21H21NO3 [M+H]+ calculated 336.15942 m/z, found 336.15970 m/z. 
N-[4-(But-2-yloxy)phenyl]-3-hydroxynaphthalene-2-carboxamide (8c). Yield 54%; Mp. 170–172 °C; 
IR (Zn/Se ATR, cm−1): 2964, 2926, 2872, 1634, 1602, 1557, 1505, 1495, 1447, 1357, 1345, 1208, 
1171, 1123, 1069, 986, 912, 868, 827, 739, 703; 1H-NMR (DMSO-d6), δ: 11.49 (s, 1H), 10.51 (s, 1H), 
8.53 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7. 64 (d, J = 9.2 Hz, 2H), 7.51 (td,  
J = 7.0 Hz, 1.1 Hz, 1H), 7.36 (td, J = 7.0 Hz, 1.1 Hz, 1H), 7.32 (s, 1H), 6.93 (d, J = 9.2 Hz, 2H), 4.36 
(sx, J = 6.0 Hz, 1H), 1.46–1.77 (m, 2H), 1.22 (d, J = 6.1 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H); 13C-NMR 
(DMSO-d6), δ: 165.60, 154.41, 154.18, 135.77, 131.10, 130.08, 128.63, 128.05, 126.75, 125.71, 
123.65, 122.35, 120.98, 115.82, 110.57, 74.40, 28.48, 18.99, 9.41; HR-MS: for C21H21NO3 [M+H]+ 
calculated 336.15942 m/z, found 336.15988 m/z. 
3.3. In Vitro Antibacterial Susceptibility Testing 
The synthesized compounds were evaluated for in vitro antibacterial activity against representatives 
of multidrug-resistant bacteria, clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) 
63718, SA 630 and SA 3202 that were obtained from the National Institute of Public Health (Prague, 
Czech Republic). Staphylococcus aureus ATCC 29213 was used as a reference and quality control 
strain. Ampicillin (Sigma-Aldrich) was used as the standard. Prior to testing, each strain was passaged 
onto nutrient agar (Oxoid, Hampshire, UK) with 5% of bovine blood, and bacterial inocula were prepared 
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by suspending a small portion of bacterial colony in sterile phosphate buffered saline (pH 7.2–7.3). 
The cell density was adjusted to 0.5 McFarland units using a densitometer (Densi-La-Meter, LIAP, Riga, 
Latvia). The final inoculum was made to a 1:20 dilution of the suspension with the Mueller-Hinton  
broth (MH broth). The compounds were dissolved in DMSO (Sigma), and the final concentration of 
DMSO in the MH broth (Oxoid) did not exceed 2.5% of the total solution composition. The final 
concentrations of the evaluated compounds ranging from 256 μg/mL to 0.008 μg/mL. The broth dilution 
micro-method modified according to NCCLS guidelines [44,45] in MH broth was used to determine the 
minimum inhibitory concentration (MIC). Drug-free controls, sterility controls and controls consisted 
of MH broth and DMSO alone were included. The determination of results was performed visually 
after 24 h of static incubation in the darkness at 37 °C in an aerobic atmosphere. The MICs were defined 
as the lowest concentration of the compound at which no visible bacterial growth was observed. The 
results are summarized in Table 1. 
3.4. In Vitro Antimycobacterial Evaluation 
Mycobacterium tuberculosis H37Ra ATCC 25177 and well characterised clinical isolate M. avium 
subsp. paratuberculosis CIT03 were grown in Middlebrook broth (MB), supplemented with  
Oleic-Albumin-Dextrose-Catalase supplement (Becton Dickinson, Oxford, UK) and mycobactin J  
(2 μg/mL). Identification of these isolates was performed using biochemical and molecular protocols. 
At log phase growth, a culture sample (10 mL) was centrifuged at 15,000 rpm/20 min using a bench 
top centrifuge (Model CR 4-12, Jouan Inc., Winchester, VA, USA). Following removal of the supernatant, 
the pellet was washed in fresh Middlebrook 7H9GC broth and re-suspended in fresh supplemented MB 
(10 mL). The turbidity was adjusted to match McFarland standard No. 1 (3 × 108 cfu) with MB broth. 
A further 1:20 dilution of the culture was then performed in MB broth. The antimicrobial susceptibility 
of all three mycobacterial species was investigated in a 96-well plate format. In these experiments, 
sterile deionised water (300 µL) was added to all outer-perimeter wells of the plates to minimize 
evaporation of the medium in the test wells during incubation. Sample wells were composed of 100 µL 
of test compound dilution and 100 µL of the bacterial stock being tested against. Dilutions of each 
compound were prepared in duplicate. For all synthesized compounds, final concentrations ranged from 
1000 μg/mL to 8 μg/mL. All compounds were prepared in DMSO and subsequent dilutions were made in 
supplemented MB. The plates were sealed with parafilm and incubated at 37 °C, for 7 days in the case 
of M. tuberculosis and 11 days in the case of M. avium subsp. paratuberculosis. Following incubation, 
a 10% addition of alamarBlue (AbD Serotec, Kidlington, UK) was mixed into each well and readings 
at 570 nm and 600 nm were taken, initially for background subtraction and subsequently after 24 h  
re-incubation. The background subtraction is necessary for strongly coloured compounds, where the 
colour may interfere with the interpretation of any colour change. For non-interfering compounds, a 
blue colour in the well was interpreted as an absence of growth and a pink colour was scored as 
growth. The minimum inhibitory concentration (MIC) was defined as the lowest concentration of the 
compound at which no visible bacterial growth was observed, i.e., the MIC is the lowest concentration 
that prevented a visual colour change from blue to pink. The MIC value is routinely and widely used in 
bacterial assays and is a standard detection limit according to the Clinical and Laboratory Standards 
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Institute (CLSI,) [27]. Rifampicin (Sigma-Aldrich) was used as the standard as it is clinically used 
antimycobacterial drugs. The results are summarized in Table 1. 
For the MTT assay, the outer wells of a 96-well plate were filled with 200 µL of sterile water, and 
the inner wells were filled with 100 µL of the tested compound at the concentration to be examined. 
Compounds were prepared as previously stated and diluted in Middlebrook media to achieve the 
desired concentration. Mycobacterium tuberculosis H37Ra ATCC 25177 was suspended in ODAC 
supplemented Middlebrook broth at a MacFarland standard of 1.0 and then diluted through a 1:20, 
using Middlebrook broth as a diluent. The diluted mycobacteria (100 µL) were added to each well 
containing the compound to be tested. A negative growth control was composed of 100 µL of DMSO 
and 100 µL of media, and the diluted mycobacteria in broth absent of inhibiting compounds were used 
as a positive growth control. All compounds and controls were prepared in triplicate. Plates were 
incubated at 37 °C for 7 days. After the incubation period, 10% well volume of MTT reagent was 
mixed into each well and incubated at 37 °C for 24 h. The reagent and media were then aspirated from 
the wells, to which 50 µL 99% isopropanol was then added, and plates were read at 570 nm. The 
absorbance readings from the cells, grown in the presence of the tested compounds, were compared 
with uninhibited cell growth (using DMSO as the blank) to determine the relative percent viability.  
The percent viability was determined through the MTT assay. The percent viability is calculated 
through comparison of a measured value against that of the uninhibited control: %viability = 
OD570E/OD570P × 100, where OD570E is the reading from the compound-exposed cells, while OD570P 
is the reading from the uninhibited cells (positive control). Cytotoxic potential is determined by a 
percent viability of <70%.  
3.5. In Vitro Cytotoxicity Assay 
Human monocytic leukemia THP-1 cells were obtained from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK; Methods of characterization: DNA Fingerprinting (Multilocus 
probes) and isoenzyme analysis). These cells were routinely cultured in RPMI 1640 (Lonza, Verviers, 
Belgium) medium supplemented with 10% fetal bovine serum (Sigma-Aldrich), 2% L-glutamine,  
1% penicillin and streptomycin (Lonza) at 37 °C with 5% CO2. Cells were passaged at approximately 
1 week intervals. Cells were routinely tested for the absence of mycoplasma (Hoechst 33258 staining 
method). The tested compounds were dissolved in DMSO (Sigma-Aldrich) and added in five increasing 
concentrations to the cell suspension in the culture medium. The maximum concentration of DMSO in 
the assays never exceeded 0.1%. Subsequently, the cells were incubated for 24 h at 37 °C with 5% 
CO2 to various compound concentrations ranging from 0.37 to 20 μM in RPMI 1640 medium. Cell 
toxicity was determined using a Cytotoxicity Detection KitPLUS Lactate dehydrogenase (LDH) assay kit 
(Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions, as described 
previously [17,18,46]. For LDH assays, cells were seeded into 96-well plates (5 × 104 cells·well−1 in 
100 μL culture medium) in triplicate in serum-free RPMI 1640 medium, and measurements at 492 nm 
wavelength (Synergy 2 Multi-Mode Microplate Reader, BioTek, Winooski, VT, USA) were taken 24 h 
after the treatment with tested compounds. The median lethal dose values, LD50, were deduced through 
the production of a dose-response curve. All data were evaluated using GraphPad Prism 5.00 software 
(GraphPad Software, San Diego, CA, USA). The results are summarized in Table 1. 
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3.6. Study of Inhibition Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [47]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Scientific Corporation), using an artificial 
electron acceptor 2,6-dichlorophenol-indophenol (DCPIP) according to Kralova et al. [48], and the rate 
of photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements 
were carried out in phosphate buffer (20.0 mM, pH 7.2) containing sucrose (0.4 M), MgCl2 (5.0 mM) 
and NaCl (15.0 mM). The chlorophyll content was 30 mg/L in these experiments and the samples were 
irradiated (~100 W/m2 with 10 cm distance) with a halogen lamp (250 W) using a 4 cm water filter to 
prevent warming of the samples (suspension temperature 22 °C). The studied compounds were dissolved 
in DMSO due to their limited aqueous solubility. The applied DMSO concentration (up to 4%) had 
negligible effect on the photochemical activity in isolated spinach chloroplasts (observed differences in 
DCPIP photoreduction due DMSO addition were within experimental error). The inhibitory efficiency of 
the studied compounds was expressed by IC50 values, i.e., by molar concentration of the compounds 
causing 50% decrease in DCPIP photoreduction relative to the untreated control. The comparable IC50 
value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-dimethylurea, DCMU (Diuron®) was about 
1.9 μM. All reagents used in this study were of analytical grade and were purchased from Sigma. The 
results are summarized in Table 1. 
The emission fluorescence spectra were recorded on a fluorescence spectrophotometer F-2000 (Hitachi, 
Tokyo, Japan) at room temperature (24 °C). The samples of chloroplast suspension (10 mg chlorophyll/L) 
with and without the studied inhibitor were excited at 436 nm, using an excitation slit 20 nm and 
emission slit 10 nm, and were kept in the dark for 2 min prior to the measurement. Due to low aqueous 
solubility the compounds were added to a chloroplast suspension in DMSO solution. The DMSO 
concentration in all samples was the same as in the control (10%). 
4. Conclusions 
A series of fifteen new N-alkoxyphenylanilides of 3-hydroxynaphthalene-2-carboxylic acid was 
prepared by means of microwave synthesis and subsequently characterized. All compounds were 
tested for their in vitro antimicrobial activity against S. aureus, three methicillin-resistant S. aureus 
strains, M. tuberculosis H37Ra and clinical isolate of M. avium subsp. paratuberculosis as well as for 
their ability to inhibit photosynthetic electron transport (PET) in spinach chloroplasts (Spinacia oleracea 
L.). 3-Hydroxy-N-(2-propoxyphenyl)naphthalene-2-carboxamide (5a) and N-[2-(but-2-yloxy)phenyl]-
3-hydroxynaphthalene-2-carboxamide (8a) showed MIC = 12 µM against all methicillin-resistant  
S. aureus strains, 4-fold higher than that of ampicillin. Compound 8a and 3-hydroxy-N-[3-(prop-2-
yloxy)phenyl]naphthalene-2-carboxamide (7b) showed MICs = 23 µM and 24 µM against M. tuberculosis 
respectively; 8a also demonstrated the highest activity (MIC = 89 µM) against M. avium subsp. 
paratuberculosis. Compound 8a was the most potent antimicrobial compound within the whole series. 
Based on the results obtained using standard MTT assay it may be hypothesized that the mechanism of 
action of the studied compounds could be connected with an effect on mycobacterial energy metabolism. 
Screening of cytotoxicity performed using the THP-1 cells proved no significant lethal effect of the 
discussed compounds except for N-[3-(but-2-yloxy)phenyl]-3-hydroxynaphthalene-2-carboxamide (8b) 
Molecules 2015, 20 9784 
 
 
that demonstrated fairly high toxicity LD50 = 2.7 ± 0.7 µM. N-(3-Ethoxyphenyl)-3-hydroxynaphthalene-
2-carboxamide (IC50 = 4.5 µM) was the most active PET inhibitor. The compounds caused 
perturbation of Chla-protein complexes in the thylakoid membrane, and the section at QB site on the 
acceptor side of PS II was estimated as inhibitory site of action of the studied compounds. Biological 
activity of the compounds is dependent on substitution of Cʹ(2) or Cʹ(3) position by the alkoxy chain and its 
bulkiness. Antimicrobial activity and cytotoxicity (strongly related to Cʹ(3) substitution) is connected 
especially with the elongation of the alkoxy tail and increasing surface activity of the compounds, while 
PET inhibition (strongly related to Cʹ(3) substitution) is connected with decreasing surface activity and a 
rather short and unbranched alkoxy chain. The effect of the additional prolongation and/or branching of 
the alkoxy tail as well as the change of the position of the phenolic moiety on the naphthalene scaffold 
has been under investigation. 
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